Dr.Reddy's Laboratories (UK) Limited

Information

Name

Type

Company

Roles

Supplier

Company Size

Sme

Company Number

Incorporation Date

Website

http://www.drreddys.com

Address

Cambridge

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Dr.Reddy's Laboratories (UK) Limited
Sign up free

Contracts awarded to Dr.Reddy's Laboratories (UK) Limited

The contracts that Dr.Reddy's Laboratories (UK) Limited have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£41,320,000 Bids close: 3 months ago
Award

Published 1 month ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£13
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 7 months ago
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 6 months ago

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£424,035,364 Bids close: 1 year ago
Award

Published 6 months ago

NHS National Framework for Transition products commencing 1 May 2024

Project title: NHS National Framework for Transition products commencing 1 May 2024 Offer reference number: CM/TNS/05/2024 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/05/2024/01 - Dimethyl fumarate, Teriflunomide, Trabectedin Lot 1 NWLN: 01/05/2024 to 31/01/2025 (9 months) Lot 2 CESW: 01/05/2024 to 30/09/2025 (17 months) Lot 3 LSNE: 01/05/2024 to 30/09/2025 (17 months) CM/TNS/05/2024/02 - Apixaban, Sapropterin Lot 1 DNW+DNE+DCE 01/05/2024 to 30/09/2025 (17 months) Lot 2 DLS+DLN+DSW 01/05/2024 to 30/09/2025 (17 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£7,559,000 Bids close: 8 months ago

Dr.Reddy's Laboratories (UK) Limited

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Dr.Reddy's Laboratories (UK) Limited

NHS National Framework for Transition products commencing 1 October 2024

NHS National Framework for Transition products commencing 1 October 2024

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

NHS National Framework for Transition products commencing 1 May 2024

Contacts

Statistics (1 Year)